Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed COO
Kaleido Biosciences, Inc. (KLDO) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/20/2021 GN Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic Therapies (MMT™) in Preventing Febrile Neutropenia
03/24/2021 GN Kaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthcare Utilization and Recovery Time in Patients with Mild-to-Moderate COVID-19 and One or More Comorbidity
03/03/2021 GN Kaleido Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results
03/01/2021 GN Kaleido Biosciences to Present at Chardan's 3rd Annual Microbiome Medicines Summit
02/11/2021 GN Kaleido Biosciences Announces the Exercise of the Underwriters' Option to Purchase Additional Shares of Common Stock
02/03/2021 GN Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
02/03/2021 GN Kaleido Biosciences Announces Proposed Public Offering of Common Stock
01/20/2021 GN Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therapy” Conference
01/05/2021 GN Kaleido Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
01/04/2021 GN Kaleido Biosciences Announces Completion of Enrollment of 350 Subjects in Controlled Study of KB109 in the Treatment of Mild-to-Moderate COVID-19
11/24/2020 GN Kaleido Biosciences to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
11/02/2020 GN Kaleido Biosciences Reports Third Quarter 2020 Financial Results and Provides Corporate Update
10/07/2020 GN Kaleido Biosciences Announces Data from MMT Programs Accepted for Presentation at Upcoming Scientific Conferences
10/06/2020 GN Kaleido Biosciences Provides Update on KB109 Clinical Data Timeline
10/01/2020 GN Kaleido Biosciences Appoints Daniel Menichella as President and Chief Executive Officer
09/29/2020 GN Kaleido Biosciences Announces First Patient Dosed in Clinical Study of Microbiome Metabolic Therapy KB295 in Patients with Mild-to-Moderate Ulcerative Colitis
08/27/2020 GN Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress™ (EASL)
08/04/2020 GN Kaleido Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy